September 3, 2024 09:43 PM EDT

Athira’s small molecule drug for Alzheimer’s fails in mid-stage study

Ryan Cross

Senior Science Correspondent

A daily injection intended to protect and regenerate brain cells has failed to slow the progression of Alzheimer’s disease in a Phase 2/3 clinical trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Athira’s small molecule drug for Alzheimer’s fails in mid-stage study

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Updated: Bristol Myers touts LAG-3 strategy in lung cancer but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing

Athi­ra’s small mol­e­cule drug for Alzheimer’s fails in mid-stage study

Senior Science Correspondent

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Athira’s small molecule drug for Alzheimer’s fails in mid-stage study